Preface

Welcome to this issue of RPACDD, Recent Patents on Anti-Cancer Drug Discovery, which publishes research articles and reviews regarding studies in relation to cancer-related patents and application of the reported patents. With the first issue of 2021, as the Editor-in-Chief, I wish to capture audiences who will be amazed by the variety of global insights provided by expert scientists. The articles in this issue include reviews and original research, as well as clinical case reports from many countries such as China, United States, India, Iran, and Saudi Arabia. I hope to communicate a larger scope to our audiences for them to understand something outside their specialty and achieve a wider perspective.

The issue encompasses a variety of topics in the field of anti-cancer drug research. There are reviews on curcumin as a natural product used for cancer prevention and treatment by Dr. Arshad Husain Rahmani and his group, and by Dr. Xiaoyu Li and colleagues on the research progress of Pathogen-Associated Molecular Patterns (PAMP) adjuvants. Furthermore, incredible advancements are being realized in the areas of cancer therapeutics and clinical strategies for various tumor types such as early-stage Testicular Germ Cell Tumor (TGCT) and Hepatocellular Carcinoma (HCC), as well as in-depth pre-clinical research that may have real-world therapeutic application further downstream, for example about the anti-proliferative effect of an anti-PSCA-peptide antibody on prostate cancer cells by Dr. Monireh Mohsenzadegan et al. Finally, there are case reports that illustrate some innovative diagnosis and treatment strategies of using combination chemotherapy/immunotherapy in cholangiocarcinoma by Dr. Liangshuai Liu, and of using Next-Generation Sequencing (NGS) for the diagnosis of leptomeningeal metastases in Non-Small Cell Lung Cancer (NSCLC) by Dr. Shuo Li et al. All of these research articles address immense challenges and may guide clinicians on future strategies in anticancer treatment and management.

I encourage you, the readers, to discover the brilliant research conducted by these scientists and hope it inspires fruitful conversations with your colleagues about the implications of these works. Particularly during this time of the COVID-19 pandemic, I thank all authors who had contributed to this issue. I would also like to express my deep appreciation to the reviewers, editorial staff, editorial board members, book review editors, frontiers section editors, section editors, regional editors, and associate editors who have given tremendous efforts in creating this issue of the journal. I hope you as the readers will enjoy the culmination of their hard work and be excited by the progress in this field as I have been.

Dr. Zhe-Sheng (Jason) Chen
(Editor-in-Chief)
Institute for Biotechnology
College of Pharmacy and Health Sciences
St. John's University
New York, NY
USA
E-mail: chenz@stjohns.edu